Is a History of Liver Disease a Contraindication to Spravato?
Spravato (esketamine) is NOT recommended in patients with severe hepatic impairment (Child-Pugh class C), but can be used with caution in mild to moderate liver disease (Child-Pugh A or B). 1
FDA-Approved Guidance on Hepatic Impairment
The FDA drug label provides clear, stage-specific guidance:
- Child-Pugh A (mild): No dose adjustment required; standard monitoring applies
- Child-Pugh B (moderate): No dose adjustment required, BUT patients require extended monitoring for adverse reactions due to higher esketamine AUC and prolonged half-life 1
- Child-Pugh C (severe): Use is NOT recommended - Spravato has not been studied in this population 1
Clinical Pharmacology Rationale
Esketamine undergoes hepatic metabolism primarily via CYP2B6 and CYP3A4 1. In moderate hepatic impairment, mean esketamine AUC and half-life values are significantly elevated compared to normal hepatic function 1. This pharmacokinetic alteration necessitates prolonged post-administration observation rather than dose reduction.
Critical distinction: Unlike many hepatically-metabolized drugs, esketamine does not require dose adjustment even in moderate impairment - instead, the monitoring period must be extended to account for delayed clearance 1.
Practical Implementation Algorithm
Step 1: Assess liver disease severity using Child-Pugh score
- Calculate based on: encephalopathy grade, ascites severity, bilirubin, albumin, and INR
- Class A (5-6 points): Proceed with standard protocol
- Class B (7-9 points): Proceed with extended monitoring
- Class C (10-15 points): Do NOT use Spravato
Step 2: For Child-Pugh A patients
- Administer standard doses (28 mg, 56 mg, or 84 mg based on indication)
- Standard 2-hour post-dose monitoring for sedation, dissociation, blood pressure elevation 2
Step 3: For Child-Pugh B patients
- Use same dosing as Child-Pugh A
- Extend monitoring beyond the standard 2-hour window 1
- Monitor specifically for: prolonged sedation, persistent dissociative symptoms, sustained blood pressure elevations
- Consider monitoring vital signs at 3-4 hours post-dose given prolonged half-life
Step 4: For Child-Pugh C patients
- Contraindicate Spravato use 1
- Consider alternative treatment strategies for treatment-resistant depression
Important Caveats
Baseline liver enzyme monitoring is NOT routinely required for asymptomatic patients receiving therapeutic doses of esketamine 3. A real-world cohort study of 104 patients found no clinically significant liver enzyme elevations attributable to ketamine or esketamine at subanesthetic doses used for depression 3.
Do not confuse therapeutic use with chronic ketamine abuse: Cholestasis and cholangiopathy reported with recreational ketamine abuse occur at substantially higher doses and frequencies than therapeutic administration 3.
Alcohol-related liver disease requires special consideration: If liver disease is alcohol-related and the patient has active alcohol use, this represents a separate contraindication due to the abuse potential of esketamine (Schedule III controlled substance) 1. The drug label specifically advises "careful consideration prior to use of individuals with a history of substance use disorder, including alcohol" 1.
Evidence Quality Note
The hepatic impairment recommendations are based on pharmacokinetic studies in non-HCV infected individuals with varying degrees of liver dysfunction 1. The absence of data in Child-Pugh C patients reflects exclusion from clinical trials rather than documented harm, but the substantial pharmacokinetic alterations in Child-Pugh B (elevated AUC and prolonged half-life) provide the scientific rationale for avoiding use in more severe disease 1.